INCLINE VILLAGE, Nev.,
June 24, 2019 /PRNewswire/
-- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI)
announces that at its 2019 annual meeting of stockholders held
June 20, 2019, the Company's
stockholders elected Natasha A.
Hernday to the Company's Board of Directors. This
appointment increases PDL's Board membership to nine, including
seven independent Directors. The Company also announced that its
stockholders voted to re-elect Harold E.
Selick, Ph.D. and Samuel R.
Saks, M.D. as Directors, and approved, on an advisory basis,
executive officer compensation.
Ms. Hernday brings to PDL approximately 25 years of
biotechnology experience and currently serves as Senior Vice
President, Corporate Development and a member of the Executive
Committee of Seattle Genetics, Inc. (Nasdaq: SGEN).
"Natasha is a seasoned pharmaceutical executive with particular
expertise in successfully executing transactions. Her experience
with in-licensing, out-licensing and mergers and acquisitions makes
her a valuable addition to our Board," said Dr. Selick, Chairman of
PDL's Board of Directors. "We look forward to calling on her
expertise when reviewing strategic transactions that offer
attractive growth potential and compelling financial returns for
PDL."
"I'm pleased to join the Board at PDL and to leverage my
experience and relationships in advancing the strategy to build a
portfolio of actively managed healthcare assets," said Ms. Hernday.
"I believe PDL has the resources and expertise to execute strategic
transactions that bring value to shareholders, while improving the
lives of patients."
During her eight years at Seattle Genetics, Ms. Hernday built
and is leading the corporate development team with responsibility
for sourcing, evaluating and negotiating licensing deals,
acquisitions and partnerships, as well as advising on corporate
strategy. Prior to Seattle Genetics, she held roles of increasing
responsibility at Amgen Inc. for 16 years, including Director,
Mergers & Acquisitions and Director, Out-Partnering. Ms.
Hernday received a BA in Biology from the University of California Santa Barbara and an MBA
from Pepperdine University.
About PDL BioPharma, Inc.
PDL's mission is to improve the lives of patients and create
value for our shareholders and our people by applying our capital
and expertise for the successful development and commercialization
of innovative therapeutics by our partner companies. We deliver on
our mission by entering into strategic transactions involving
innovative late clinical-stage or early commercial-stage
therapeutics with attractive revenue growth potential.
NOTE: PDL, PDL BioPharma, the PDL logo and associated logos and
the PDL BioPharma logo are trademarks or registered trademarks of,
and are proprietary to, PDL BioPharma, Inc. which reserves all
rights therein.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/natasha-a-hernday-elected-to-pdl-biopharmas-board-of-directors-300873134.html
SOURCE PDL BioPharma, Inc.